Castle Biosciences, Inc.’s DecisionDx-SCC Better IDs High-risk Immune-suppressed SCC Patients Who Need ART
Castle Biosciences, Inc.’s DecisionDx-SCC test provides more precise risk stratification than Brigham and Women’s Hospital (BWH) staging alone for guiding intensified treatment of immune-suppressed patients with high-risk cutaneous squamous cell carcinoma (SCC). DecisionDx-SCC is a 40-gene expression profile test that uses an individual patient’s tumor biology to stratify risk of metastasis in patients with cutaneous […]